Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3048 |
|
| Actual shortage: | 226 (7%) | |
| Anticipated shortage: | 14 (0%) | |
| Avoided shortage: | 9 (0%) | |
| Resolved: | 2799 (92%) | |
Discontinuation Reports |
356 |
|
| To be discontinued: | 22 (6%) | |
| Discontinued: | 334 (94%) | |
| Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
31 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-OLANZAPINE ODT | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2018-12-12 | 2019-03-29 | 69318 |
| APO-OLANZAPINE ODT | 15MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2019-09-04 | 2019-10-01 | 92984 |
| APO-OLANZAPINE ODT | 15MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2019-12-05 | 2020-01-07 | 100310 |
| APO-OLANZAPINE ODT | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2020-04-13 | 2020-12-21 | 111928 |
| APO-OLANZAPINE ODT | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2020-04-13 | 2020-12-21 | 111931 |
| APO-OLANZAPINE ODT | 15MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2020-05-08 | 2020-12-28 | 114309 |
| APO-OLANZAPINE ODT | 20MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2020-05-08 | 2020-12-28 | 114312 |
| APO-OLANZAPINE ODT | 20MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2021-10-29 | 2021-11-26 | 148503 |
| APO-OLANZAPINE ODT | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2021-10-29 | 2021-12-06 | 148506 |
| APO-OLANZAPINE ODT | 20MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2022-05-20 | 2022-07-22 | 161032 |
| APO-OLANZAPINE ODT | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2022-06-17 | 2022-07-28 | 162904 |
| APO-OLANZAPINE ODT | 15MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2023-03-02 | 2023-06-02 | 185930 |
| APO-OLANZAPINE ODT | 20MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2023-04-06 | 2023-06-02 | 188968 |
| APO-OLANZAPINE ODT | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2023-04-27 | 2023-06-02 | 190862 |
| APO-OLANZAPINE ODT | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2023-05-19 | 2023-06-02 | 192788 |
| APO-OLANZAPINE ODT | 5MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2023-06-29 | 2023-11-06 | 196949 |
| APO-OLANZAPINE ODT | 20MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2023-07-21 | 2023-11-06 | 199515 |
| APO-OLANZAPINE ODT | 20MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2023-12-15 | 2024-01-05 | 213553 |
| APO-OLANZAPINE ODT | 15MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2023-12-15 | 2024-01-05 | 213576 |
| APO-OLANZAPINE ODT | 10MG | TABLET (ORALLY DISINTEGRATING) | Resolved | 2023-12-22 | 2024-01-05 | 214223 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
| APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-04-01 | 217493 |
| APO-CARVEDILOL | 3.125MG | TABLET | To be discontinued | 2024-01-26 | 2024-01-26 | 217496 |